1. 尊龙凯时,尊龙凯时医药集团股份公司官网,尊龙凯时医药集团股份公司,尊龙凯时甾体激素,尊龙凯时麻醉药品

      About Us

      Global

      R&D

      Investor Relations

      About Us

      Leading the pharmaceutical industry to become a superior provider of pharmaceutical products and services.

      1993 Year
      Founded in 1993
      2000 +
      There are more than 2083 pharmaceutical R&D personnel
      70 +
      Export to 70 countries and regions
      500 +
      The group is developing 500 products
      820 +
      822 patents granted
      1993 Year
      Founded in 1993
      2000 +
      There are more than 2083 pharmaceutical R&D personnel
      70 +
      Export to 70 countries and regions
      500 +
      The group is developing 500 products
      820 +
      822 patents granted
      Global

      Adhere to R&D innovation and international expansion.

      EPIC Pharma

      St. Louis Research and Development Center

      PuraCap Pharmaceutical

      Humanwell Pharma Mali

      Humanwell Pharma Afrique

      Humanwell Pharmaceutical Ethiopia

      YiChang Humanwell Pharmaceutical

      Humanwell Puracap Phamaceuticals (Wuhan)

      Likang Pharmaceutical

      Paion Pharma

      Paion UK

      Xinjiang Xipa Pharmaceutical

      EPIC Pharma

      Having the qualifications for the production and operation of controlled drugs and holding over 60 ANDA approvals; Having a mature sales network in the US market; A CMO site recognized by multinational pharmaceutical companies for a long time.

      St. Louis Research and Development Center

      The company's important strategic layout for promoting internationalization includes cutting-edge information research, new drug discovery and exploration, high-end formulation research and industrialization, and coordinated development with the international registration, production, export, and independent marketing of the company's products. Focusing on strategic areas such as anesthesia, analgesia, and central nervous system diseases, there are products under research in innovative drugs, high-end sustained-release formulations, and complex injection formulations.

      PuraCap Pharmaceutical

      PuraCap Pharmaceuticals LLC, established in 2008 in New Jersey, is among the earliest Chineses-backed pharmaceutical companies in the USA. The company is engaged in the market entry and distribution of OTC products in the US, and its specialty products are soft gel capsules.

      Humanwell Pharma Mali

      Commercial pharmaceutical company covering eight French speaking regions in West Africa

      Humanwell Pharma Afrique

      The first modern pharmaceutical factory in West Africa, ending the history of Mali being unable to produce drugs; Production of injectable, oral solid/liquid and other preparations

      Humanwell Pharmaceutical Ethiopia

      Modern pharmaceutical factories in Ethiopia; the first pharmaceutical factory invested in and constructed by a Hubei enterprise in Ethiopia; production of oral solid/liquid formulations and small volume injections.

      YiChang Humanwell Pharmaceutical

      The first oral solid dosage form factory in Hubei Province to be certified by the US FDA and the UK MHRA; Focus on the research and development, registration, production, and international sales of sustained-release oral solid preparations and transdermal generic drugs that meet national standards.

      Humanwell Puracap Phamaceuticals (Wuhan)

      The first soft capsule production enterprise in Hubei Province to pass the US FDA certification; Leading supplier of soft capsule drug formulations in the US market; A leading enterprise in the research and production of global soft capsule drug formulations.

      Likang Pharmaceutical

      Having dual qualifications from NMPA and FDA, covering injections and high-end oral solid preparations, we undertake the entire process of clinical sample to commercial production commissioning business.

      Paion Pharma

      Headquartered in Aachen of Germany, the company focuses on the R&D and commercialization of innovative pharmaceutical products for anesthesia and critical care.

      Xinjiang Xipa Pharmaceutical

      The company established a subsidiary in the Republic of Uzbekistan in 2016, and established a professional marketing academic promotion team and registration team. The company has registered six kinds of Uyghur medicines, and the sales scope covers the entire territory of Uzbekistan.

      Continue to build and improve the high-end technology platform, and promote the technology transfer and introduction of new products through industry-university-research cooperation.

      More than 500 products under development, projects and more than 60 new drugs of category 1 and 2 under development

      822 authorized patents, 407 invention patents, and 74 overseas authorized patents

      Covering Europe, the United States, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, Taiwan, China and other countries and regions


      Continuously building and improving high-end technology platforms, promoting technology transfer and introduction of new products through industry university research cooperation

      While building a first-class R&D innovation platform, we provide comprehensive services for new drug research, development, clinical trials, and registration


      We have a research team centered around overseas pharmaceutical experts, domestic pharmaceutical PhDs, and master’s degree holders

      There are over 2,000 R&D personnel, including more than 120 PhDs, and 9 experts who enjoy special allowances from the State Council

      Investor Relations
      Periodical Ad-hoc
      网站地图